Article
Cardiac & Cardiovascular Systems
James P. Curtain, Carly Adamson, Toru Kondo, Jawad Butt, Akshay S. Desai, Faiez Zannad, Jean L. Rouleau, Luis E. Rohde, Lars Kober, Inder S. Anand, Dirk J. van Veldhuisen, Michael R. Zile, Martin P. Lefkowitz, Scott D. Solomon, Milton Packer, Mark C. Petrie, Pardeep S. Jhund, John J. McMurray
Summary: This study examined the incidence of ventricular tachycardia (VT) and ventricular fibrillation (VF) in patients with heart failure and their relationship with mortality. The results showed that VT/VF events were uncommon but strongly associated with mortality in heart failure patients. These events seem to be markers of disease severity rather than risk of sudden death.
EUROPEAN HEART JOURNAL
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Shuang Li, Yining Wang, Wenjing Yang, Di Zhou, Baiyan Zhuang, Jing Xu, Jian He, Gang Yin, Xiaohan Fan, Weichun Wu, Piyush Sharma, Arlene Sirajuddin, Andrew E. Arai, Shihua Zhao, Minjie Lu
Summary: This retrospective study aimed to identify clinical and cardiac MRI risk factors for adverse events in patients with dilated cardiomyopathy (DCM) and left ventricular ejection fraction (LVEF) of 35% or higher. The results showed that myocardial scar at late gadolinium enhancement (LGE) MRI equal to or greater than 7.1% of the LV mass was associated with sudden cardiac death (SCD) or aborted SCD.
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Javed Butler, Dimitrios Farmakis, Faiez Zannad, Anne Pernille Ofstad, Joao Pedro Ferreira, Jennifer B. Green, Julio Rosenstock, Sven Schnaidt, Martina Brueckmann, Stuart J. Pocock, Milton Packer, Stefan D. Anker
Summary: In patients with heart failure and preserved ejection fraction, empagliflozin significantly reduces the risk of heart failure outcomes, regardless of diabetes status at baseline.
Article
Cardiac & Cardiovascular Systems
Luis E. Rohde, Muthiah Vaduganathan, Brian L. Claggett, Carisi A. Polanczyk, Pranav Dorbala, Milton Packer, Akshay S. Desai, Michael Zile, Jean Rouleau, Karl Swedberg, Martin Lefkowitz, Victor Shi, John J. V. McMurray, Scott D. Solomon
Summary: This study found that integrating time-varying covariates significantly improved the prediction assessment of sudden cardiac death. Models combining baseline variables with time-updated variables independently predicted SCD risk, helping improve risk stratification and differentiate modes of death in chronic heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2021)
Article
Cardiac & Cardiovascular Systems
Sebastian Rosch, Karl-Patrik Kresoja, Christian Besler, Karl Fengler, Anne Rebecca Schoeber, Maximilian von Roeder, Christian Luecke, Matthias Gutberlet, Karin Klingel, Holger Thiele, Karl-Philipp Rommel, Philipp Lurz
Summary: In this study, patients with heart failure with preserved ejection fraction (HFpEF) were stratified based on left ventricular ejection fraction (LVEF), resulting in distinct morphologic and pathophysiologic subphenotypes. Patients with LVEF ranging from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction, while patients with LVEF >60% exhibited a hypercontractile state with excessive left ventricular afterload and diminished preload reserve.
Article
Cardiac & Cardiovascular Systems
You-Jung Choi, Hyung-Kwan Kim, In-Chang Hwang, Chan Soon Park, Tae-Min Rhee, Hyun-Jung Lee, Jun-Bean Park, Yeonyee Elizabeth Yoon, Seung-Pyo Lee, Goo-Yeong Cho, Yong-Jin Kim
Summary: The study aimed to investigate the association between low-normal left ventricular ejection fraction (LVEF) and adverse outcomes in hypertrophic cardiomyopathy (HCM), as well as evaluate the predictive power of LVEF in the conventional HCM sudden cardiac death (SCD)-risk model. The results showed that low-normal LVEF was an independent predictor of heart failure hospitalization and cardiovascular death in patients with HCM.
Article
Cardiac & Cardiovascular Systems
Akshay S. Desai, Muthiah Vaduganathan, John G. Cleland, Brian L. Claggett, Ebrahim Barkoudah, Peter Finn, Finnian R. McCausland, Mehmet B. Yilmaz, Martin Lefkowitz, Victor Shi, Marc A. Pfeffer, John J. V. McMurray, Scott D. Solomon
Summary: In patients with heart failure and preserved left ventricular ejection fraction, those with lower EF had higher rates of cardiovascular and sudden death, while non-cardiovascular death rates increased with higher EF. Regardless of EF, sacubitril/valsartan did not reduce death from any cause compared with valsartan.
CIRCULATION-HEART FAILURE
(2021)
Article
Multidisciplinary Sciences
Maria Calderon-Dominguez, Thalia Belmonte, Maribel Quezada-Feijoo, Monica Ramos, Juan Calderon-Dominguez, Oscar Campuzano, Alipio Mangas, Rocio Toro
Summary: The study found that microRNA profiles can categorize DCM patients based on their EF, enabling the identification of high-risk individuals. A three-microRNA signature combined with clinical variables was identified as a potential novel prognostic biomarker with high clinical value for categorizing idiopathic DCM.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Andreas Hain, Nikolai Busch, Said Elias Waezsada, Julie Hutter, Patrick Kahle, Malte Kuniss, Thomas Neumann, Tsyuoshi Masuda, Horst O. Esser, Christian Hamm, Johannes Sperzel
Summary: Monitoring heart rate with a wearable cardioverter/defibrillator (WCD) provides important prognostic information and may assist in optimal usage of beta blockers in patients with heart failure.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Urology & Nephrology
Katherine Scovner Ravi, Thomas A. Mavrakanas, David M. Charytan, Finnian R. Mc Causland
Summary: The study found that the association of LVEF with cardiac arrest and heart failure hospitalization is attenuated at lower levels of kidney function. However, there was limited effect on all-cause mortality. Further research is needed to identify the factors beyond LVEF that drive these observations.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Multidisciplinary Sciences
Jae Hyung Cho, Derek Leong, Natasha Cuk, Joseph E. Ebinger, Catherine Bresee, Sung-Han Yoon, Ashkan Ehdaie, Michael Shehata, Xunzhang Wang, Sumeet S. Chugh, Eduardo Marban, Eugenio Cingolani
Summary: This study investigates the prevalence of ventricular arrhythmias (VT) in patients with heart failure and preserved ejection fraction (HFpEF), finding that VT is more common in HFpEF patients and is associated with prolonged QTc interval.
Article
Chemistry, Analytical
Henrike Aenne Katrin Hillmann, Stephan Hohmann, Johanna Mueller-Leisse, Christos Zormpas, Joerg Eiringhaus, Johann Bauersachs, Christian Veltmann, David Duncker
Summary: This study evaluated the clinical relevance of the wearable cardioverter-defibrillator (WCD) in patients with newly diagnosed heart failure and reduced ejection fraction (HFrEF), finding that HRV5 could serve as an independent predictor for LVEF improvement.
Article
Cardiac & Cardiovascular Systems
Li Shen, Pardeep S. Jhund, Inder S. Anand, Peter E. Carson, Akshay S. Desai, Christopher B. Granger, Lars Kober, Michel Komajda, Robert S. McKelvie, Marc A. Pfeffer, Scott D. Solomon, Karl Swedberg, Michael R. Zile, John J. McMurray
Summary: The clinical models can predict risks for SD and PFD separately with good discrimination and calibration in HFpEF and are robust in external validation. Adding NT-proBNP further improved model performance. These models may help to identify high-risk individuals for device intervention in future trials.
CLINICAL RESEARCH IN CARDIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Jasneet K. Devgun, Samuel Kennedy, Jeremy Slivnick, Zachary Garrett, Katherine Dodd, Mohamed H. Derbala, Cristina Ortiz, Sakima A. Smith
Summary: This article discusses patients with heart failure and recovered ejection fraction, where the recovery of LVEF does not necessarily mean complete remission from heart failure. The utility of defibrillators in these patients, as well as predictors for recovery and risk of ventricular arrhythmias, are also explored. Novel imaging parameters have been identified to potentially aid in predicting arrhythmia risk, and there is also a small risk of arrhythmias and appropriate shocks in these patients.
Article
Cardiac & Cardiovascular Systems
Eric J. Hall, Soumojit Pal, Michael S. Glennon, Puneeth Shridhar, Sidney L. Satterfield, Beth Weber, Qinkun Zhang, Guy Salama, Hind Lal, Jason R. Becker
Summary: Cardiac natriuretic peptides play a crucial role in regulating cardiovascular physiology. Deficiency in either atrial natriuretic peptide (ANP) or B-type natriuretic peptide (BNP) can cause adverse effects on the structure and function of the heart. This study shows that ANP and BNP exert non-redundant functions in maintaining myocardial cGMP levels, which in turn regulate the activity of cardiomyocyte p38 mitogen-activated protein kinase (p38 MAPK) and cAMP response element-binding protein (CREB). Deficiency in cardiac natriuretic peptides increases the risk of stress-induced ventricular arrhythmias.
CARDIOVASCULAR RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Safia Chatur, Brian L. Claggett, Orly Vardeny, Karola Jering, Akshay S. Desai, Marc A. Pfeffer, Martin Lefkowitz, John J. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Summary: In HFpEF, the use of SACUBITRIL/VALSARTAN may reduce the risk of heart failure events and have an impact on diuretic requirements. The safety profile of SACUBITRIL/VALSARTAN remains consistent regardless of baseline diuretic dose.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Transplantation
Phil McEwan, Rebecca Boyce, Juan Jose Garcia Sanchez, C. David Sjostrom, Bergur Stefansson, Stephen Nolan, Ricardo Correa-Rotter, Peter Rossing, Glenn M. Chertow, John J. McMurray, David C. Wheeler, Hiddo J. L. Heerspink
Summary: The DAPA-CKD trial demonstrated that dapagliflozin has significant benefits in patients with chronic kidney disease and albuminuria. Using a Markov model, it was predicted that dapagliflozin treatment would lead to longer time in lower CKD stages, reduced mortality, and fewer complications such as heart failure and kidney function decline.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Medicine, General & Internal
Meir Schechter, Niels Jongs, Glenn M. Chertow, Ofri Mosenzon, John J. McMurray, Ricardo Correa-Rotter, Peter Rossing, Anna Maria Langkilde, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink
Summary: This study aimed to determine the effects of dapagliflozin on hospitalizations in patients with chronic kidney disease (CKD). The results showed that dapagliflozin reduced the risk of hospitalization for any cause in patients with CKD, regardless of whether they had type 2 diabetes or not.
ANNALS OF INTERNAL MEDICINE
(2023)
Editorial Material
Rheumatology
Nathalie Conrad, Iain B. McInnes, John J. Mcmurray, Naveed Sattar
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Cardiac & Cardiovascular Systems
Mikhail N. Kosiborod, Ankeet S. Bhatt, Brian L. Claggett, Muthiah Vaduganathan, Ian J. Kulac, Carolyn S. P. Lam, Adrian F. Hernandez, Felipe A. Martinez, Silvio E. Inzucchi, Sanjiv J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, James C. Fang, Yaling Han, Josep Comin-Colet, Orly Vardeny, Daniel Lindholm, Ulrica Wilderaeng, Olof Bengtsson, John J. V. McMurray, Scott D. Solomon
Summary: In the DELIVER trial, dapagliflozin was found to significantly improve the health status of heart failure patients, as assessed by the Kansas City Cardiomyopathy Questionnaire. The effects were particularly pronounced in patients with higher baseline symptom burden.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Editorial Material
Endocrinology & Metabolism
Naveed Sattar, John J. McMurray, Iain B. McInnes, Vanita R. Aroda, Mike E. J. Lean
Summary: Few people reach old age without taking multiple drugs and undergoing investigations, often due to chronic conditions caused or exacerbated by excess adiposity. Weight management, which is rarely discussed or attempted, can play a role in addressing these conditions. There is a need for more research on the effects of effective weight management on age and weight-mediated symptoms.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Carly Adamson, Paul Welsh, Kieran F. Docherty, Rudolf A. de Boer, Mirta Diez, Jaroslaw Drozdz, Andre Dukat, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Charlotta E. A. Ljungman, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, David A. Morrow, Daniel Lindholm, Ann Hammarstedt, David W. Boulton, Peter J. Greasley, Anna Maria Langkilde, Scott D. Solomon, Naveed Sattar, John J. V. McMurray, Pardeep S. Jhund
Summary: Elevation in IGFBP-7 is associated with worse clinical outcomes in patients with heart failure with reduced ejection fraction. IGFBP-7 provides prognostic information incremental to clinical variables, NT-proBNP, and hsTnT. Dapagliflozin does not modulate IGFBP-7 levels.
JACC-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Mark C. Petrie, Pardeep S. Jhund, Naveed Sattar, Akshay S. Desai, Lars Kober, Jean L. Rouleau, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Milton Packer, John J. McMurray
Summary: This study found that newer anthropometric measures such as waist-to-height ratio, rather than body mass index (BMI), accurately predicted the risk of heart failure hospitalization and cardiovascular death in patients with heart failure. The study also showed a positive correlation between waist-to-height ratio and higher levels of obesity, as well as increased risk of heart failure hospitalization.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Paolo Tolomeo, Jawad H. Butt, Toru Kondo, Gianluca Campo, Akshay S. Desai, Pardeep S. Jhund, Lars Kober, Martin P. Lefkowitz, Jean L. Rouleau, Scott D. Solomon, Karl Swedberg, Muthiah Vaduganathan, Michael R. Zile, Milton Packer, John J. McMurray
Summary: The 2021 CKD-EPI equation combining creatinine and cystatin C provides a better estimation of GFR compared to the creatinine-only equation. The creatinine-cystatin equation led to a substantial reclassification of chronic kidney disease stages and was associated with higher mortality and worsening of clinical scores in heart failure patients.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Pascal R. D. Clephas, Sumant P. Radhoe, Eric Boersma, John Gregson, Pardeep S. Jhund, William T. Abraham, John J. McMurray, Rudolf A. de Boer, Jasper J. Brugts
Summary: A meta-analysis of large randomized trials showed that remote monitoring of pulmonary artery pressure and adjusting treatment can reduce hospital admissions for heart failure.
EUROPEAN HEART JOURNAL
(2023)
Correction
Biochemistry & Molecular Biology
Orly Vardeny, James C. C. Fang, Akshay S. S. Desai, Pardeep S. S. Jhund, Brian Claggett, Muthiah Vaduganathan, Rudolf A. A. de Boer, Adrian F. F. Hernandez, Carolyn S. P. Lam, Silvio E. E. Inzucchi, Felipe A. A. Martinez, Mikhail N. N. Kosiborod, David DeMets, Eileen O'Meara, Shelley Zieroth, Josep Comin-Colet, Jaroslaw Drozdz, Chern-En Chiang, Masafumi Kitakaze, Magnus Petersson, Daniel Lindholm, Anna Maria Langkilde, John J. V. McMurray, Scott D. D. Solomon
Article
Cardiac & Cardiovascular Systems
Glenn M. Chertow, Ricardo Correa-Rotter, Priya Vart, Niels Jongs, John J. V. McMurray, Peter Rossing, Anna Maria Langkilde, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink
Summary: In the DAPA-CKD trial, dapagliflozin was found to reduce the risk of kidney and cardiovascular events in patients with chronic kidney disease and albuminuria. The treatment effect of dapagliflozin was consistent regardless of baseline cardiovascular medication use.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Toru Kondo, Pooja Dewan, Inder S. Anand, Akshay S. Desai, Milton Packer, Michael R. Zile, Marc A. Pfeffer, Scott D. Solomon, William T. Abraham, Sanjiv J. Shah, Carolyn S. P. Lam, Pardeep S. Jhund, John J. V. Mcmurray
Summary: By analyzing LVEF data in HF patients, we found that there is a threshold between 40% and 50% LVEF, below which the pattern of patient characteristics changes, and event rates begin to increase. This provides support for the current prognosis-based definition of HF with mildly reduced ejection fraction based on upper LVEF thresholds.
Article
Cardiac & Cardiovascular Systems
Bo Ye, Amy D. Bradshaw, Juan E. Abrahante, Julie A. Dragon, Tim N. Haeussler, Stephen P. Bell, Fuyuki Hirashima, Martin LeWinter, Michael R. Zile, Markus Meyer
Summary: Heart failure with preserved ejection fraction (HFpEF) is a common condition with limited treatments. The molecular mechanisms and signaling pathways underlying HFpEF development are not well understood. This study analyzed gene expression in left ventricular biopsies from HFpEF patients and identified profibrotic pathways but no proinflammatory signature.
CIRCULATION-HEART FAILURE
(2023)